In related news, other scientists recently reported that phospho-tau isoforms in the CSF mirror protofibrillar forms of tau, ...

On November 14, 2024, the EMA granted approval for Lecanemab in the European Union ... the brain called positron emission tomography (PET). This non-invasive method furnishes direct ...

The full result from Eisai’s large, global phase 3 confirmatory Clarity AD clinical study of lecanemab – an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of ...

is the amyloid-beta (Aβ) plaque, which could not be detected during life until recently. Advances have permitted its detection in cerebrospinal fluid and with positron emission tomography (PET ...

This is important because with continuous administration, LEQEMBI clears highly toxic protofibrils* which can continue to cause neuronal injury even after the amyloid-beta (Aβ) plaque has been ...

This indicates that the amount of CSF Lec-PF is more strongly associated with neurodegeneration than the accumulation of Aβ in the brain. (Cerebrospinal fluid (CSF) lecanemab-associated amyloid ...

Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for once every four weeks lecanemab ...